WuXi Biologics to Build Facility for $3 Billion Vaccine in Ireland

WuXi Biologics will build a vaccine facility in Ireland for its major product, an innovative vaccine developed by an unnamed global vaccine company. Earlier this year, when the vaccine partnership was announced, WuXi said the product would generate $3 billion in revenues over the 20 year life of the contract. So far, WuXi has not disclosed the name of the partner, but it did say the "first of its kind" vaccine would be distributed to global markets. Local Irish sources say the vaccine facility will be a 15,500 square meter plant. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues: